Protocol or clinical trial simulations have been on the radar screen of the industry for quite some time as a technique for optimizing trial design and decision making.
Why is it so hard to develop drugs for children with cancer? And what can be done about it? Those questions are central to a new study published in JAMA Oncology that explores new business models for funding drug development to treat pediatric cancers.
This three-part article series will look at how best to procure, manage, and implement best practices in this complicated market.
Ron Squarer believes for a company to be successful, especially in a capital-intensive area such as biotechnology, it has to know what it is good at and target those skills. Squarer is the CEO of Array BioPharma, a company focused on the discovery, development, and commercialization of targeted, small-molecule drugs to treat patients with cancer.
Recent revisions to the International Council for Harmonisation (ICH) Guideline for Good Clinical Practice, as outlined in ICH E6 (R2), have provided an impetus for sponsors to reevaluate their oversight and quality management processes throughout the clinical development process.
Six leading CROs, along with cloud-computing vendor Veeva Systems, have banded together to form Align Clinical CRO, a new industry standards group that hopes to make it easier for CROs and sponsors to work together. But Align Clinical CRO is not the first attempt to bring standards to the information discrepancies that arise between sponsors and CROs during clinical trials.
The clinical operations team at CSL Behring has come a long way in the six and a half years since Mark Ridge joined the organization. The company is now executing on its goal of being a sponsor of choice for patients, sites, and CROs.
Consumer awareness of the quality of goods purchased is good practice in any industry, but in biotech and pharma, it is a regulatory requirement. One of the most common goods we purchase in this industry is a vendor’s services — their time, effort, and resources. Whether it be a lab, CRO, or data management group, the FDA mandates we, as sponsor companies, know the quality of the goods and services we purchase from them.
A problem that seems to impact everyone involved in clinical research is the current shortage of CRAs. This problem is causing excessive turnover at CROs, climbing CRA wages, and frustration for sponsors who have to deal with changing staff members at their CRO. Can a new partnership help solve the problem?
Dan Peres, SVP and head of medical for Immuron, works with a pipeline that includes treatments for ASH, Diabetes, C-Diff, Colitis, NASH, and UPEC. Peres recently spoke to me about the challenges of performing trials and the process of scaling up to a large, Phase 3 study.
|
|
|
|
|
|
|
|
|